Ablation

Tumor Ablation Market Size Worth $2.4 Billion By 2028 | CAGR: 13.2%: Grand View Research, Inc.

Retrieved on: 
Thursday, February 4, 2021
Ablation, Cancer, Interventional radiology, Medicine, Clinical medicine, Medical specialties, Medical physics, Surgical oncology

SAN FRANCISCO, Feb. 4, 2021 /PRNewswire/ -- The global tumor ablation market size is estimatedto reach USD 2.4 billion by 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 4, 2021 /PRNewswire/ -- The global tumor ablation market size is estimatedto reach USD 2.4 billion by 2028, according to a new report by Grand View Research, Inc.
  • The increasing incidence of cancer and high demand for effective treatment options are the major factors driving the market growth.
  • According to Cancer Research U.K., the incidence rate of cancer is expected to grow by 62.0% from 2018 to 2040.
  • Grand View Research has segmented the global tumor ablation market on the basis of technology, treatment, application, and region:
    Tumor Ablation Technology Outlook (Volume, Units; Revenue, USD Million, 2016 - 2028)

Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation

Retrieved on: 
Friday, January 29, 2021
Medicine, Interventional radiology, Clinical medicine, Medical specialties, Surgical oncology, Medical terminology, Radiofrequency ablation, Ablation, Sensei robotic catheter system

The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Key Points: 
  • The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.
  • The DTA system delivers real-time feedback on physical parameters, which can guide physicians as the lesion is being produced.
  • "DTA is the only FDA-approved, temperature-controlled, irrigated RF ablation system on the market today.
  • DIAMOND-AF is the largest completed AF ablation technology IDE trial which resulted in FDA approval to date.

CathVision clinical results to be presented at the AF Symposium

Retrieved on: 
Friday, January 29, 2021
Ablation, Catheter ablation

The study compared the performance of the CathVision Cube recording system to that of an existing market leader.

Key Points: 
  • The study compared the performance of the CathVision Cube recording system to that of an existing market leader.
  • "We are proud to present results from our first in human study at the highly respected AF Symposium conference," said CEO Mads Emil Matthiesen.
  • "We thank Professor Josef Kautzner and his team at IKEM for using CathVision Cube during cardiac ablation procedures in their patients.
  • The results are from the first in a series of product evaluation studies that will continue throughout 2021.

Acutus Medical Suite of EP Products To Be Featured During Recorded Cases at AF Symposium 2021

Retrieved on: 
Thursday, January 28, 2021
Atrial fibrillation, Cardiac arrhythmia, Arrhythmia, Ablation

CARLSBAD, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB) today announced the presentation of two mapping and ablation procedures during the 26th Annual International AF Symposium demonstrating the beneficial capabilities of guided ablation therapy utilizing the companys entire diagnostic and therapeutic suite of EP products.

Key Points: 
  • CARLSBAD, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Acutus) (Nasdaq: AFIB) today announced the presentation of two mapping and ablation procedures during the 26th Annual International AF Symposium demonstrating the beneficial capabilities of guided ablation therapy utilizing the companys entire diagnostic and therapeutic suite of EP products.
  • AF prevalence is increasing, and effective and efficient treatment is necessary to meet the growing patient demand for ablation procedures.
  • Acutus is focused on developing and advancing technology that makes it easier for physicians to improve outcomes and shorten procedure times, said Vince Burgess, CEO, Acutus Medical.
  • Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated.

MedLumics Proprietary Technology to be presented at 26th Annual International AF Symposium

Retrieved on: 
Thursday, January 28, 2021
Medicine, Clinical medicine, Medical specialties, Interventional radiology, Surgical oncology, Plasma physics, Medical terminology, Radiofrequency ablation, Ablation, Cardiac electrophysiology

The presentation, entitled 'Direct Lesion Assessment using Photonics during AF ablation', will cover the first preclinical use of MedLumics' biophotonic technology with RadioFrequency Ablation (RFA) and Pulsed Field Ablation (PFA).

Key Points: 
  • The presentation, entitled 'Direct Lesion Assessment using Photonics during AF ablation', will cover the first preclinical use of MedLumics' biophotonic technology with RadioFrequency Ablation (RFA) and Pulsed Field Ablation (PFA).
  • Recent preclinical studies have been successful in demonstrating reliable monitoring of the continuity and transmurality of the cardiac tissue ablation in real-time.
  • Medlumics' optically guided technology, AblaView, enables the electrophysiologist to confirm device contact, stability and lesion assessment in real time.
  • Medlumics Ireland Ltd. is a subsidiary and IDA company developing automated optical sensor and packaging processes for high volume manufacture.

MedLumics Proprietary Technology to be presented at 26th Annual International AF Symposium

Retrieved on: 
Thursday, January 28, 2021
Medicine, Clinical medicine, Medical specialties, Cardiac arrhythmia, Interventional radiology, Medical terminology, Radiofrequency ablation, Surgical oncology, Catheter ablation, Atrial fibrillation, Cardiac electrophysiology, Ablation

MADRID, Jan. 28, 2021 /PRNewswire/ -- MedLumics, a privately held medical technology company developing AblaView, an optically-guided RadioFrequency (RF) catheter ablation system for the treatment of Atrial Fibrillation (AF), announced today the first public communication on its technology using photonics during AF ablation at the upcoming 26th Annual International AF Symposium 2021 , being held virtually from 29-31 January 2021.

Key Points: 
  • MADRID, Jan. 28, 2021 /PRNewswire/ -- MedLumics, a privately held medical technology company developing AblaView, an optically-guided RadioFrequency (RF) catheter ablation system for the treatment of Atrial Fibrillation (AF), announced today the first public communication on its technology using photonics during AF ablation at the upcoming 26th Annual International AF Symposium 2021 , being held virtually from 29-31 January 2021.
  • The presentation, entitled 'Direct Lesion Assessment using Photonics during AF ablation', will cover the first preclinical use of MedLumics' biophotonic technology with RadioFrequency Ablation (RFA) and Pulsed Field Ablation (PFA).
  • Medlumics' optically guided technology, AblaView, enables the electrophysiologist to confirm device contact, stability and lesion assessment in real time.
  • Medlumics Ireland Ltd. is a subsidiary and IDA company developing automated optical sensor and packaging processes for high volume manufacture.

Radiofrequency Ablation Devices Market Revenue Worth $11,080.3 Million by 2030: P&S Intelligence

Retrieved on: 
Monday, January 18, 2021
Medicine, Clinical medicine, Medical specialties, Medical terminology, Radiofrequency ablation, Surgical oncology, Ablation, Catheter

This factor is projected to drive the global radiofrequency ablation devices market at a healthy 12.6% CAGR between 2020 and 2030.

Key Points: 
  • This factor is projected to drive the global radiofrequency ablation devices market at a healthy 12.6% CAGR between 2020 and 2030.
  • At this rate, the revenue generated by market players will rise from $3,173.5 million in 2019 to $11,080.3 million in 2030, according to P&S Intelligence.
  • The rising popularity of MISs is driving the radiofrequency ablation devices market as RFA is becoming the preferred MIS procedure for pain management and numerous cardiac diseases.
  • Throughout the next decade, the radiofrequency ablation devices market will be dominated by the catheter systems category, under the component segment.

Radiofrequency Ablation Devices Market Revenue Worth $11,080.3 Million by 2030: P&S Intelligence

Retrieved on: 
Monday, January 18, 2021
Medicine, Clinical medicine, Medical specialties, Medical terminology, Radiofrequency ablation, Surgical oncology, Ablation, Catheter

This factor is projected to drive the global radiofrequency ablation devices market at a healthy 12.6% CAGR between 2020 and 2030.

Key Points: 
  • This factor is projected to drive the global radiofrequency ablation devices market at a healthy 12.6% CAGR between 2020 and 2030.
  • At this rate, the revenue generated by market players will rise from $3,173.5 million in 2019 to $11,080.3 million in 2030, according to P&S Intelligence.
  • The rising popularity of MISs is driving the radiofrequency ablation devices market as RFA is becoming the preferred MIS procedure for pain management and numerous cardiac diseases.
  • Throughout the next decade, the radiofrequency ablation devices market will be dominated by the catheter systems category, under the component segment.

CardioFocus Invited To Participate In 23rd Annual ICR Conference And Needham Virtual Growth Conference

Retrieved on: 
Tuesday, January 12, 2021
Plasma physics, Heartlight, Ablation, PVI, Atrial fibrillation

The company has also been invited to attend the 23rd Annual Needham Virtual Growth Conference , being held virtually January 11-15, 2021.

Key Points: 
  • The company has also been invited to attend the 23rd Annual Needham Virtual Growth Conference , being held virtually January 11-15, 2021.
  • The HeartLight X3 System is a next-generation AFib ablation technology, building upon the advanced features of the HeartLight Endoscopic Ablation System.
  • The system performs pulmonary vein isolation (PVI) using laser energy to create lines of scar tissue to block the abnormal electrical pathways that cause AFib.
  • Using direct tissue visualization, titratable laser energy and compliant balloon technology, the HeartLight X3 System offers a unique RAPID mode.

CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal

Retrieved on: 
Monday, January 11, 2021
Medical technology, Medicine, Equipment, Microport, Microport, Cardiac arrhythmia, Heartlight, Atrial fibrillation, Port, Ablation

MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ -- CardioFocus, Inc ., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ -- CardioFocus, Inc ., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.
  • "Based on the success in France, we believe MicroPort will achieve rapid HeartLight X3 adoption in both Spain and Portugal."
  • "We are convinced our collaboration in Europe with CardioFocus is a win-win partnership," said Philippe Wanstok, SVP Global Sales and Marketing at MicroPort CRM.
  • "The HeartLight X3 ablation system is the perfect complement to our MicroPort EP range of catheters and Columbus 3D imaging system.